JDD case reports

Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
Tofacitinib INTRODUCTION Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …
Tofacitinib
Intralesional Bleomycin Combined With Cryotherapy in the Treatment of Recalcitrant Verruca Vulgaris
BleomycinVerruca vulgaris is a common cutaneous manifestation of Human Papillomavirus (HPV) infection that presents as hyperkeratotic, cauliflower-like papules with central black petechiae. These lesions may be resistant to conventional therapies, posing a therapeutic challenge and prolong significant morbidity for the patient. This case report demonstrates an immediate and robust response of recalcitrant …
Bleomycin
Pyoderma Gangrenosum Occurring in the Setting of Hypercortisolism
Pyoderma GangrenosumPyoderma Gangrenosum Occurring in the Setting of Hypercortisolism Associated With Adrenocortical Adenoma: A Pathophysiological Paradox Pyoderma gangrenosum (PG) is a challenging, rare, ulcerating skin disease characterized by neutrophilic abundance and absence of infection, often associated with systemic diseases. JDD authors Chapman Wei, Elizabeth Hazuka, Peter DeRosa, Jill M. Paulson MD, and Ad …
Pyoderma Gangrenosum
Recalcitrant Dyshidrotic Eczema Treated With Dupilumab
eczemaThe following two cases presented by JDD authors Ryan A. Gall MD, John D. Peters MD, and Alyson J. Brinker MD add to the growing literature supporting the use of dupilumab in the treatment of patients with recalcitrant dyshidrotic eczema, both with and without diagnosed contact allergens. Introduction Dyshidrotic eczema, also known as dyshidrosis or pompholyx when involving larger bullae, is a c …
eczema